The cocoa butter equivalent market is growing steadily, driven by high cocoa prices, sustainability trends, and confectionery demand. Innovations in plant-based fats and expanding use in food, cosmetics, and North America support continued market expansion.

Cocoa Butter Equivalent Market Trends & Forecast
According to a research study published by Knowledge Sourcing Intelligence (KSI), the cocoa butter equivalent market will expand from USD 1,479.7 million in 2025 to USD 2,004.9 million in 2030 at a CAGR of 6.3% during the forecast period.
The cocoa butter equivalent (CBE) market is experiencing robust growth, driven by the need for cost efficiency, rising sustainability expectations, and the functional advantages CBEs offer in product formulation.
Companies that prioritise clean-label and sustainable CBEs and focus on expanding their presence into emerging markets are well-positioned to lead the industry. Recent innovations in the sector include the development of CBEs using non-hydrogenated and fractionated plant-based fats.
Request a free sample copy or view the report summary: Cocoa Butter Equivalent Market Report
Cocoa Butter Equivalent Market Highlights
By source, the cocoa butter equivalent market is segmented into palm oil, coconut oil, shea butter, and others. Shea butter is expected to grow at a considerable rate fueled by its natural properties and ethical sourcing, which make it highly applicable in premium cosmetics and chocolates.
By distribution channel, the cocoa butter equivalent market is segmented into online and offline, where the offline channels dominate the market as they involves large-scale business-to-business transactions that require bulk purchases particularly in food and cosmetic sectors. Moreover, the physical interaction also ensures quality assurance compliance with global food safety standards.
By application, the cocoa butter equivalent market is segmented into food and beverages, cosmetics, pharmaceuticals, and others. The food & beverage sector accounts for major market share driven by growing chocolate & confectionary consumption globally which is driving the demand for cost-efficient alternatives by manufacturers to scale production.
North America will account for a considerable market share, as major regional economies like the United States is one of the major cocoa importers, and with the growing demand for confectionery products, the demand for cost-effective alternatives providing the same taste & flavors and price utility is expected to show growth in the country. Moreover, the growing health consciousness and awareness regarding the usage of plant-based ingredients have furthered the overall market growth.
Cocoa Butter Equivalent Market Growth Drivers and Restraints
Growth Drivers:
High Cocoa Butter Prices and Supply Instability: The limited cocoa beans supply caused by climatic change and other geopolitical factors has led to price volatility for such beans which is pushing manufacturers towards more affordable alternatives. CBE such as made from palm oil is becoming a favourable choice for manufacturers who are focused on maintaining product quality at a lower production cost.
Growing Demand for Confectionery Products: The demand for cocoa butter equivalent products is increasing in diverse food options mainly in confectionery and chocolate owing to the growing emphasis to provide cost-effective products with consistent texture. Moreover, the growing usage of natural ingredients in non-food applications such as cosmetics has provided new growth prospects for shea butter-based CBEs thereby augmenting the overall market growth.
Restraints:
Technical and Formulation Challenge: To match cocoa butter’s sensory properties, CBE requires adjustments in recipes, processing, and storage to achieve the same texture. Such adjustments require high technical expertise and high R&D costs which slows the overall production duration. Similarly, quality concerns, including perceived inferiority, authenticity debates, health issues, and sustainability challenges, significantly hinder the market’s growth, particularly in premium and health-conscious segments.
Cocoa Butter Equivalent Market Key Development
Joint Venture: In October 2025, AAK formed a joint venture with Kuala Lumpur Kepong Berhad (KLK) called “Nura Specialty Oils and Fats” which will improve AAK’s access to high-purity feedstock used in producing cocoa butter alternative.
Cocoa Butter Equivalent Market Segmentation
Knowledge Sourcing Intelligence has segmented the Cocoa Butter Equivalent Market based on material type, industry vertical, application, and region:
Cocoa Butter Equivalent Market, By Material Type
Palm Oil
Coconut Oil
Shea Butter
Others
Cocoa Butter Equivalent Market By Distribution Channel
Online
Offline
Cocoa Butter Equivalent Market, By Applications
Food and Beverages
Cosmetics
Pharmaceutical
Others
Cocoa Butter Equivalent Market, By Region
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
Israel
Others
Asia Pacific
China
Japan
South Korea
India
Thailand
Indonesia
Others
Cocoa Butter Equivalent Market Key Players
Cargill, Incorporated
Usha Edible Oil
Wilmar International Ltd
Manorama Industries Limited
Makendi Worldwide
Intercontinental Speciality Fats Sdn. Bhd.
Fuji oil co. ltd (Idemitsu Kosan Co.,Ltd)
Mewah Group
Olam International Limited
FGV IFFCO SDN BHD
Bunge
Olenex Sàrl
AAK AB
Blommer Chocolate
Need specialized data cuts or competitive intelligence?
Our analyst team provides bespoke market sizing, supplier audits, and country-level feasibility reports tailored to your enterprise roadmap.
Speak With an Industry Analyst →Ask an Industry Analyst
Have questions regarding this briefing or market projections? Inquire with our sector lead.
Related Press Releases
View All →
ADC Manufacturing & CDMO Market is expected to reach USD 10.49 billion by 2031
Aug 7, 2026
Lifestyle-Associated Cancer Epidemiology Market is expected to reach USD 13.12 billion by 2031
Aug 5, 2026
Psycho-Oncology Digital Health Market is anticipated to surpass USD 290.01 million in 2031 at a CAGR of 8.5%
Jul 30, 2026
Intratumoral Injection Therapy Market is expected to reach USD 630.39 million by 2031
Jul 24, 2026
Palliative Care in Oncology Market is expected to reach USD 244.1 billion by 2031
Jul 22, 2026More Press Releases
Oncology Drug Resistance Testing Market is projected to reach USD 3.41 billion in 2031 at a CAGR of 6.6 %
The oncology drug resistance testing market is expanding due to rising cancer prevalence, increasing drug resistance, and growing adoption of precision oncology. Advances in NGS-based testing, companion diagnostics, and targeted therapies, alongside FDA approvals and investments in personalized medicine, are accelerating demand for effective resistance monitoring across hospitals and clinical diagnostics worldwide.
TROP-2 Targeted Therapy Market is anticipated to surpass USD 3.29 billion in 2031 at a CAGR of 8.6 %
The TROP-2 Targeted Therapy market is expanding rapidly due to increasing precision oncology adoption, rising cancer prevalence, and growing use of antibody-drug conjugates. North America leads the market, while Asia Pacific shows the fastest growth. Continuous clinical trials, regulatory approvals, and strategic collaborations are accelerating innovation and commercial adoption worldwide.
Second Primary Cancer Prevention Market is expected to reach USD 24.7 billion by 2031
The Second primary cancer prevention refers to strategies aimed at reducing the risk of developing a new, unrelated cancer in individuals with a prior cancer diagnosis. Growing cancer survivorship, advances in treatment, and increasing awareness of long-term health outcomes have heightened the importance of prevention and surveillance programs. Key approaches include routine screening, genetic risk assessment, lifestyle modification, and long-term follow-up care. Government agencies and healthcare organisations increasingly emphasise survivorship care plans and evidence-based screening protocols to detect new malignancies at earlier stages. Continued investments in early detection technologies and personalised risk assessment are expected to support advancements in second primary cancer prevention.